CY1124897T1 - Τροποποιημενα εξωκυτταρικα κυστιδια και χρησεις αυτων - Google Patents
Τροποποιημενα εξωκυτταρικα κυστιδια και χρησεις αυτωνInfo
- Publication number
- CY1124897T1 CY1124897T1 CY20221100020T CY221100020T CY1124897T1 CY 1124897 T1 CY1124897 T1 CY 1124897T1 CY 20221100020 T CY20221100020 T CY 20221100020T CY 221100020 T CY221100020 T CY 221100020T CY 1124897 T1 CY1124897 T1 CY 1124897T1
- Authority
- CY
- Cyprus
- Prior art keywords
- exosomes
- protein
- therapeutic
- luminal surface
- exosome
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 abstract 10
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 102000004169 proteins and genes Human genes 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 5
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα αποκάλυψη αφορά θεραπευτικά εξωσώματα εμπλουτισμένα σε πρωτεΐνες που υπάρχουν στην επιφάνεια αυλού των εξωσωμάτων. Η παρούσα αποκάλυψη παρέχει μεθόδους κατασκευής εξωσωμάτων εμπλουτισμένων σε πρωτεΐνες που υπάρχουν στην επιφάνεια αυλού των εξωσωμάτων, μία μέθοδο σύνδεσης ενός θεραπευτικού πεπτιδίου ή πρωτεΐνης με την επιφάνεια αυλού των εξωσωμάτων και μία μέθοδο χρήσης, π.χ., μεθόδους θεραπευτικής ή διαγνωστικής χρήσης. Οι μέθοδοι κατασκευής περιλαμβάνουν παραγωγή τροποποιημένων εξωσωμάτων της επιφάνειας του αυλού που περιλαμβάνουν ένα ή περισσότερα από τα EV, π.χ., πρωτεΐνες εξωσώματος σε συγκεντρώσεις υψηλότερες από αυτές που παρατηρούνται σε εξωσώματα αγρίου τύπου, μία τροποποίηση ή ένα θραύσμα του EV, π.χ., πρωτεΐνη εξωσώματος, ή μία πρωτεΐνη συγχώνευσης του EV, π.χ., πρωτεΐνη εξωσώματος, και ένα ωφέλιμο φορτίο, π.χ., βιολογικά δραστικό μόριο όπως μία θεραπευτική πρωτεΐνη.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/061679 WO2019099942A1 (en) | 2017-11-17 | 2018-11-16 | Compositions of engineered exosomes and methods of loading luminal exosomes payloads |
| US201962835430P | 2019-04-17 | 2019-04-17 | |
| PCT/US2019/033629 WO2020101740A1 (en) | 2018-11-16 | 2019-05-22 | Engineered extracellular vesicles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124897T1 true CY1124897T1 (el) | 2023-01-05 |
Family
ID=70732111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100020T CY1124897T1 (el) | 2018-11-16 | 2022-01-07 | Τροποποιημενα εξωκυτταρικα κυστιδια και χρησεις αυτων |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP3672614B1 (el) |
| JP (2) | JP7538795B2 (el) |
| KR (1) | KR20210098473A (el) |
| CN (1) | CN113286603A (el) |
| AU (1) | AU2019378591A1 (el) |
| BR (1) | BR112021009231A2 (el) |
| CA (1) | CA3119720A1 (el) |
| CL (1) | CL2021001278A1 (el) |
| CY (1) | CY1124897T1 (el) |
| DK (1) | DK3672614T3 (el) |
| EA (1) | EA202191334A1 (el) |
| ES (1) | ES2907967T3 (el) |
| HR (1) | HRP20220020T1 (el) |
| HU (1) | HUE057300T2 (el) |
| IL (1) | IL283167A (el) |
| LT (1) | LT3672614T (el) |
| MA (1) | MA49971B1 (el) |
| MD (1) | MD3672614T2 (el) |
| MX (1) | MX2021005636A (el) |
| PH (1) | PH12021551088A1 (el) |
| PL (1) | PL3672614T3 (el) |
| PT (1) | PT3672614T (el) |
| RS (1) | RS62863B1 (el) |
| SG (1) | SG11202104956QA (el) |
| SI (1) | SI3672614T1 (el) |
| TW (1) | TWI846697B (el) |
| WO (1) | WO2020101740A1 (el) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220323519A1 (en) * | 2019-04-17 | 2022-10-13 | Codiak Biosciences, Inc. | Compositions of exosomes and aav |
| WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| AU2020328611A1 (en) * | 2019-08-14 | 2022-03-03 | Lonza Sales Ag | Extracellular vesicle-aso constructs targeting STAT6 |
| WO2021030768A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
| BR112022002690A2 (pt) | 2019-08-14 | 2022-08-23 | Codiak Biosciences Inc | Construtos de vesícula-aso extracelular tendo como alvo cebp/beta |
| JP2022544290A (ja) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ， インコーポレイテッド | Ｋｒａｓを標的とするアンチセンスオリゴヌクレオチドを有する細胞外小胞 |
| WO2021062057A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Exogenous loading of exosomes via lyophilization |
| CN114727947A (zh) | 2019-09-25 | 2022-07-08 | 科迪亚克生物科学公司 | 细胞外囊泡组合物 |
| WO2021062058A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| WO2021062290A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
| EP4034150A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
| CN115484990A (zh) | 2020-03-12 | 2022-12-16 | 基础科学研究院 | 诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法 |
| WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
| US20230114434A1 (en) | 2020-03-13 | 2023-04-13 | Codiak Biosciences, Inc. | Extracellular vesicles for treating neurological disorders |
| WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| JP2023518414A (ja) | 2020-03-20 | 2023-05-01 | コディアック バイオサイエンシーズ， インコーポレイテッド | 治療のための細胞外小胞 |
| WO2021248133A1 (en) | 2020-06-05 | 2021-12-09 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| CN116209430A (zh) * | 2020-08-07 | 2023-06-02 | 阿米库斯治疗学公司 | 囊泡靶向蛋白及其用途 |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| WO2022066934A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| GB202015399D0 (en) * | 2020-09-29 | 2020-11-11 | Evox Therapeutics Ltd | Engineered extracellular vesicles displaying enhanced pharmacokinetics |
| WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
| CN112899307A (zh) * | 2021-01-28 | 2021-06-04 | 苏州大学 | GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用 |
| US20240167036A1 (en) * | 2021-02-17 | 2024-05-23 | Lonza Sales Ag | Extracellular vesicle-nlrp3 antagonist |
| WO2022178147A1 (en) | 2021-02-17 | 2022-08-25 | Codiak Biosciences, Inc. | Methods of loading extracellular vesicles |
| WO2022212884A1 (en) | 2021-04-01 | 2022-10-06 | Codiak Biosciences, Inc. | Extracellular vesicle compositions |
| CN114057893B (zh) * | 2021-04-26 | 2022-12-30 | 苏州大学 | 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用 |
| CN117126886A (zh) * | 2022-05-20 | 2023-11-28 | 谛邈生物科技(北京)有限公司 | 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用 |
| WO2023229366A1 (en) * | 2022-05-24 | 2023-11-30 | Shiftbio Co., Ltd. | Surface-engineered extracellular vesicles and therapeutic uses thereof |
| WO2024226723A1 (en) * | 2023-04-26 | 2024-10-31 | Northwestern University | Active loading of biomolecular cargo into engineered vesicles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| PL2254586T3 (pl) * | 2008-02-22 | 2015-09-30 | Agency For Science Tech And Research Astarstar | Cząstki mezenchymalnych komórek macierzystych |
| FR2950350B1 (fr) | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
| EP3164420A4 (en) * | 2014-06-30 | 2018-05-23 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| WO2016138525A1 (en) * | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
| US10617768B2 (en) * | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
| US20210290556A1 (en) * | 2016-08-22 | 2021-09-23 | Codiak Biosciences, Inc. | Methods of suppressing delivery of exosomes to liver and spleen |
| WO2018112154A1 (en) * | 2016-12-15 | 2018-06-21 | Codiak Biosciences, Inc. | Methods of measuring exosomes using intrinsic fluorescence |
| WO2019040920A1 (en) | 2017-08-25 | 2019-02-28 | Codiak Biosciences, Inc. | PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS |
| WO2019099942A1 (en) * | 2017-11-17 | 2019-05-23 | Codiak Biosciences, Inc. | Compositions of engineered exosomes and methods of loading luminal exosomes payloads |
| EP3841112A1 (en) * | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
-
2019
- 2019-05-22 JP JP2021526563A patent/JP7538795B2/ja active Active
- 2019-05-22 ES ES19731027T patent/ES2907967T3/es active Active
- 2019-05-22 CN CN201980083366.0A patent/CN113286603A/zh active Pending
- 2019-05-22 CA CA3119720A patent/CA3119720A1/en active Pending
- 2019-05-22 WO PCT/US2019/033629 patent/WO2020101740A1/en unknown
- 2019-05-22 SG SG11202104956QA patent/SG11202104956QA/en unknown
- 2019-05-22 EP EP19731027.9A patent/EP3672614B1/en active Active
- 2019-05-22 HU HUE19731027A patent/HUE057300T2/hu unknown
- 2019-05-22 HR HRP20220020TT patent/HRP20220020T1/hr unknown
- 2019-05-22 EA EA202191334A patent/EA202191334A1/ru unknown
- 2019-05-22 MX MX2021005636A patent/MX2021005636A/es unknown
- 2019-05-22 AU AU2019378591A patent/AU2019378591A1/en active Pending
- 2019-05-22 EP EP21200884.1A patent/EP4059510A1/en active Pending
- 2019-05-22 DK DK19731027.9T patent/DK3672614T3/da active
- 2019-05-22 PT PT197310279T patent/PT3672614T/pt unknown
- 2019-05-22 SI SI201930182T patent/SI3672614T1/sl unknown
- 2019-05-22 LT LTEPPCT/US2019/033629T patent/LT3672614T/lt unknown
- 2019-05-22 BR BR112021009231-5A patent/BR112021009231A2/pt unknown
- 2019-05-22 MD MDE20200694T patent/MD3672614T2/ro unknown
- 2019-05-22 MA MA49971A patent/MA49971B1/fr unknown
- 2019-05-22 KR KR1020217018358A patent/KR20210098473A/ko active Search and Examination
- 2019-05-22 PL PL19731027T patent/PL3672614T3/pl unknown
- 2019-05-22 RS RS20220009A patent/RS62863B1/sr unknown
- 2019-05-23 TW TW108117910A patent/TWI846697B/zh active
-
2021
- 2021-05-11 PH PH12021551088A patent/PH12021551088A1/en unknown
- 2021-05-13 IL IL283167A patent/IL283167A/en unknown
- 2021-05-14 CL CL2021001278A patent/CL2021001278A1/es unknown
-
2022
- 2022-01-07 CY CY20221100020T patent/CY1124897T1/el unknown
-
2024
- 2024-05-10 JP JP2024077013A patent/JP2024097929A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA49971A (fr) | 2020-07-01 |
| MX2021005636A (es) | 2021-07-06 |
| PH12021551088A1 (en) | 2022-01-03 |
| IL283167A (en) | 2021-06-30 |
| HRP20220020T1 (hr) | 2022-04-01 |
| EP4059510A1 (en) | 2022-09-21 |
| EP3672614A1 (en) | 2020-07-01 |
| TWI846697B (zh) | 2024-07-01 |
| SI3672614T1 (sl) | 2022-04-29 |
| ES2907967T3 (es) | 2022-04-27 |
| LT3672614T (lt) | 2022-04-11 |
| PT3672614T (pt) | 2022-02-11 |
| RS62863B1 (sr) | 2022-02-28 |
| BR112021009231A2 (pt) | 2021-08-10 |
| MA49971B1 (fr) | 2022-01-31 |
| KR20210098473A (ko) | 2021-08-10 |
| WO2020101740A1 (en) | 2020-05-22 |
| CA3119720A1 (en) | 2020-05-22 |
| DK3672614T3 (da) | 2022-01-10 |
| PL3672614T3 (pl) | 2022-03-07 |
| WO2020101740A9 (en) | 2021-06-10 |
| CN113286603A (zh) | 2021-08-20 |
| EP3672614B1 (en) | 2021-10-06 |
| CL2021001278A1 (es) | 2022-03-11 |
| TW202038993A (zh) | 2020-11-01 |
| HUE057300T2 (hu) | 2022-05-28 |
| MD3672614T2 (ro) | 2022-04-30 |
| JP2024097929A (ja) | 2024-07-19 |
| SG11202104956QA (en) | 2021-06-29 |
| EA202191334A1 (ru) | 2022-02-10 |
| JP2022513049A (ja) | 2022-02-07 |
| AU2019378591A1 (en) | 2021-06-17 |
| JP7538795B2 (ja) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124897T1 (el) | Τροποποιημενα εξωκυτταρικα κυστιδια και χρησεις αυτων | |
| AR115159A1 (es) | Vesículas extracelulares modificadas y usos de las mismas | |
| CY1125109T1 (el) | Θεραπειες toy καρκινου | |
| CY1123555T1 (el) | Συμπλοκο πρωτεϊνης ιντερλευκινης 15 και χρηση αυτου | |
| CY1122948T1 (el) | 1η-πυρρολο[2,3-c]πυριδιν-7(6η)-ονες και πυραζολο[3,4-c]πυριδιν-7(6η)-ονες ως αναστολεις των βετ πρωτεϊνων | |
| CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
| CY1122494T1 (el) | Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων | |
| CY1122195T1 (el) | Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων | |
| CY1123858T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
| WO2019040920A8 (en) | PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS | |
| CY1125373T1 (el) | Λιπιδικα νανοσωματιδια για την παροχη τροποποιημενου rna που κωδικοποιει ενα πολυπεπτιδιο vegf-a | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CY1122107T1 (el) | Τροποποιημενες πρωτεϊνες δεσμευσης οι οποιες αναστελλουν την αλληλεπιδραση υποδοχεα vegf-a | |
| CY1124778T1 (el) | Αντισωματα anti-asic1 και χρησεις αυτων | |
| CY1120485T1 (el) | Μεθοδοι για τη συζευξη πεπτιδιων-στοχων με ανασυνδυασμενα λυσοσωμικα ενζυμα για βελτιωμενες θεραπευτικες αγωγες διαταραχων λυσοσωμικης αποθηκευσης | |
| CY1118714T1 (el) | Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2 | |
| CO6640254A2 (es) | Método para preparar anticuerpos con propiedades mejoradas | |
| UY36539A (es) | Proteínas de unión a icos | |
| CY1125102T1 (el) | Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| AR076977A1 (es) | Proteinas precursoras repetitivas autoensambladas | |
| PH12017501520A1 (en) | Fusarium toxin-cleaving polypeptide variants, additives containing same, use of same, and method for splitting fusarium toxins | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| MX2020000288A (es) | Cromatografia. | |
| CY1124238T1 (el) | Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης |